Closing Humira Inquiry, Ombudsman Advises EMA On Future Trial Data Redaction
This article was originally published in SRA
The European Ombudsman, Emily O'Reilly, has closed her inquiry into the European Medicines Agency's release of a number of redacted clinical trial study reports on AbbVie's MAb Humira (adalimumab), and has made a number of recommendations as to what the agency needs to do to ensure that the maximum amount of trial data is made publicly accessible in future1.
You may also be interested in...
The EU’s new health commissioner, Stella Kyriakides, has outlined the commission’s plans for dealing with medicines access issues in the EU member states. They include completing the review of the EU pediatric and orphan legislation and developing a new strategic plan to tackle shortages and affordability problems next year.
AstraZeneca’s Lynparza can now be used on the Scottish National Health Service for newly diagnosed advanced ovarian cancer.
As stockpiles of Ebola vaccine are being built up around the world, Médecins sans Frontières has said more action is needed to ensure sufficient numbers of vaccinations are available for use in current and future outbreaks.